Stephens & Co. Reiterates Overweight on CareDx, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Mason Carrico reiterated an Overweight rating on CareDx (NASDAQ:CDNA) and maintained a $15 price target.
April 17, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stephens & Co. reaffirmed an Overweight rating on CareDx, with a $15 price target, indicating a positive outlook on the stock.
The reiteration of an Overweight rating and maintenance of a $15 price target by Stephens & Co. suggests a strong belief in CareDx's future performance. This positive analyst outlook can influence investor sentiment and potentially lead to a short-term increase in CDNA's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100